European commission approves kaftrio® in combination with ivacaftor for the treatment of children with cystic fibrosis ages 2 through 5

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the european commission has granted approval for the label expansion of kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis (cf) ages 2 through 5 years old who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene. “in addition to data from clinical trials, long-term.
VRTX Ratings Summary
VRTX Quant Ranking